Moderna expects Phase 1 data for multivalent Coronavirus Vaccine sooner than May

• At Barclays Global Healthcare Conference, Moderna (MRNA +6.3%) has announced that the company expects to have Phase 1 data sooner than May for the multivalent coronavirus vaccine against the Wuhan strain and South African variant.
• According to details posted on the federal database of clinical trials, the Phase 1 open-label study will evaluate the safety and efficacy of mRNA-1273 and mRNA-1273.351 vaccines as its primary objective.
• Just yesterday, the company announced the dosing initiation of the Phase 2 trial for booster vaccine candidates against the B.1.351 variant first identified in South Africa.